WeVote
Log In

Bill

Bill

S 4826

Concerns health information held by certain biotechnology companies.

2024-2025 Regular Session Introduced by Teresa Ruiz

New Jersey Senate bill addressing health information privacy and security practices by biotechnology companies; referred to Health committee.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
#humansvcs
0
WeVote Research Nonpartisan
Bill Summary · S 4826

Legislative bill overview

S 4826 addresses the handling and protection of health information maintained by biotechnology companies operating in New Jersey. The bill was recently introduced and referred to the Senate Health committee for review. Specific provisions have not yet been publicly detailed in available legislative records.

Why is this important

Biotechnology companies increasingly collect sensitive genetic, medical, and biological data that raises privacy and security concerns. Clear regulatory frameworks are essential to protect New Jersey residents' health information from misuse, unauthorized access, or commercialization while allowing legitimate research and innovation.

Potential points of contention

  • Data privacy scope: Disagreement over which biotechnology activities should be regulated and what constitutes "health information" requiring protection
  • Industry compliance burden: Concerns from biotech companies about regulatory costs, competitive disadvantages, and whether requirements exceed federal HIPAA standards
  • Research access vs. privacy: Tension between protecting individual privacy and enabling beneficial medical research, genetic studies, or public health initiatives that require data access

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.